CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 552 products for "CDK". Showing the first 500.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK7-IN-1
CAS:CDK7-IN-1, analog of YKL-5-124, inhibits cdk7 with IC50 < 100 nM.Formula:C28H35N7O3Color and Shape:SolidMolecular weight:517.634Cimpuciclib
CAS:Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.Formula:C30H35FN8OColor and Shape:SolidMolecular weight:542.663TMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Formula:C40H43BrFN9O11SColor and Shape:SolidMolecular weight:956.791[pThr3]-CDK5 Substrate
CAS:[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1].Formula:C53H100N15O15PPurity:98%Color and Shape:SolidMolecular weight:1218.43CDK7-IN-21
CAS:CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] .Formula:C33H36FN9O2Color and Shape:SolidMolecular weight:609.7CDK4/6-IN-23
CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.Formula:C32H34FN7O4Color and Shape:SolidMolecular weight:599.655BSJ-03-204
CAS:BSJ-03-204 is a selective Cdk4/6 degrader.Formula:C43H48N10O8Color and Shape:SolidMolecular weight:832.9[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Formula:C98H138F3N21O39Purity:98%Color and Shape:SolidMolecular weight:2291.25(1S,3R,5R)-PIM447 dihydrochloride
(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).Formula:C24H25Cl2F3N4OPurity:98%Color and Shape:SolidMolecular weight:513.38IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Formula:C23H32FN5O2SiColor and Shape:SolidMolecular weight:457.625CDK1-IN-2
CAS:CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.Formula:C17H11ClN2OPurity:98.53%Color and Shape:SoildMolecular weight:294.73Ref: TM-T64373
1mg52.00€1mL*10mM (DMSO)98.00€5mg102.00€10mg166.00€25mg334.00€50mg537.00€100mg767.00€500mg1,558.00€CDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Formula:C22H28ClFN6O4SColor and Shape:SolidMolecular weight:527.01PP-C8
PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.Formula:C43H51FN12O7Color and Shape:SolidMolecular weight:866.94Cell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);Color and Shape:Odour SolidRef: TM-L8100
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireCDK2-IN-43
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.464CDK7-IN-5
CAS:CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).Formula:C34H45N9O2Color and Shape:SolidMolecular weight:611.795JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formula:C53H69N5O9Purity:98%Color and Shape:SolidMolecular weight:920.161CDK7/9-IN-1
CAS:CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.Formula:C24H32F3N5O2Color and Shape:SolidMolecular weight:479.548Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Color and Shape:Odour SolidRef: TM-L1600
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireFDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Color and Shape:LiquidRef: TM-L1610
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquire
![[pThr3]-CDK5 Substrate](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1602.webp&w=3840&q=75)
